These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 16632010)

  • 41. [Retrospective assessment of effective and safety of cinacalcet for the treatment of secondary hyperparathyroidism depending on basal iPTH level].
    Mercadal Orfila G; Blasco Mascaró I
    Farm Hosp; 2012; 36(1):11-5. PubMed ID: 21514862
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism.
    Messa P; Macário F; Yaqoob M; Bouman K; Braun J; von Albertini B; Brink H; Maduell F; Graf H; Frazão JM; Bos WJ; Torregrosa V; Saha H; Reichel H; Wilkie M; Zani VJ; Molemans B; Carter D; Locatelli F
    Clin J Am Soc Nephrol; 2008 Jan; 3(1):36-45. PubMed ID: 18178780
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Calcimimetics in chronic kidney disease: evidence, opportunities and challenges.
    Evenepoel P
    Kidney Int; 2008 Aug; 74(3):265-75. PubMed ID: 18528328
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial.
    Parfrey PS; Chertow GM; Block GA; Correa-Rotter R; Drüeke TB; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Dehmel B; Trotman ML; Modafferi DM; Goodman WG
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4834-44. PubMed ID: 24108314
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevention of uremic bone disease using calcimimetic compounds.
    Olgaard K; Lewin E
    Annu Rev Med; 2001; 52():203-20. PubMed ID: 11160775
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Calcimimetics treatment strategy for serum calcium and phosphate management in patients with secondary hyperparathyroidism undergoing dialysis: A systematic review and meta-analysis of randomized studies.
    Nakai K; Kono K; Yamada S; Taniguchi M; Hamano T; Fukagawa M
    Ther Apher Dial; 2024 Aug; 28(4):557-571. PubMed ID: 38499495
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study.
    Ureña P; Jacobson SH; Zitt E; Vervloet M; Malberti F; Ashman N; Leavey S; Rix M; Os I; Saha H; Ryba M; Bencova V; Baños A; Zani V; Fouque D
    Nephrol Dial Transplant; 2009 Sep; 24(9):2852-9. PubMed ID: 19369690
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Calcimimetics for predialysis patients?
    Fournier A; Shahapuni I; Harbouche L; Monge M
    Am J Kidney Dis; 2006 Jan; 47(1):196; author reply 196-7. PubMed ID: 16377407
    [No Abstract]   [Full Text] [Related]  

  • 49. Efficacy and safety of cinacalcet compared with other treatments for secondary hyperparathyroidism in patients with chronic kidney disease or end-stage renal disease: a meta-analysis.
    Sun Y; Tian B; Sheng Z; Wan P; Xu T; Yao L
    BMC Nephrol; 2020 Jul; 21(1):316. PubMed ID: 32736534
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in end-stage renal disease: a UK perspective.
    Garside R; Pitt M; Anderson R; Mealing S; D'Souza R; Stein K
    Nephrol Dial Transplant; 2007 May; 22(5):1428-36. PubMed ID: 17308322
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cinacalcet: new drug. Secondary hyperparathyroidism: where are the clinical data?
    Prescrire Int; 2006 Jun; 15(83):90-3. PubMed ID: 16764095
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Parathyroid and bone. Calcimimetics and bone metabolism].
    Fukumoto S
    Clin Calcium; 2007 Dec; 17(12):1865-9. PubMed ID: 18057662
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Calcimimmetic and calcilytics: new perspectives of correction of abnormal parathormone (PTH) secretion].
    Rybczyńska A; Hoppe A
    Przegl Lek; 2003; 60(6):418-24. PubMed ID: 14974181
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of cinacalcet treatment on serum soluble Klotho levels in haemodialysis patients with secondary hyperparathyroidism.
    Komaba H; Koizumi M; Tanaka H; Takahashi H; Sawada K; Kakuta T; Fukagawa M
    Nephrol Dial Transplant; 2012 May; 27(5):1967-9. PubMed ID: 22140124
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency.
    Mizobuchi M; Hatamura I; Ogata H; Saji F; Uda S; Shiizaki K; Sakaguchi T; Negi S; Kinugasa E; Koshikawa S; Akizawa T
    J Am Soc Nephrol; 2004 Oct; 15(10):2579-87. PubMed ID: 15466262
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.
    Arenas MD; Alvarez-Ude F; Gil MT; Moledous A; Malek T; Nuñez C; Devesa R; Carretón MA; Soriano A
    Nephrol Dial Transplant; 2007 Jun; 22(6):1639-44. PubMed ID: 17277339
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Parathyroidectomy in the calcimimetic era.
    Elder GJ
    Nephrology (Carlton); 2005 Oct; 10(5):511-5. PubMed ID: 16221104
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial.
    Chertow GM; Correa-Rotter R; Block GA; Drueke TB; Floege J; Goodman WG; Herzog CA; Kubo Y; London GM; Mahaffey KW; Mix TC; Moe SM; Wheeler DC; Parfrey PS
    Nephrol Dial Transplant; 2012 Jul; 27(7):2872-9. PubMed ID: 22529163
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
    Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Calcimimetics--a new treatment for hyperparathyroidism?].
    Piecha G; Chudek J; Wiecek A
    Pol Merkur Lekarski; 2005 May; 18(107):581-4. PubMed ID: 16161961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.